IL2 and neoplasm: In an attempt to reduce the severe toxic side effects caused by systemic exposure of high-dose IL-2, we used as a backbone a thymidine kinase (TK), and vaccinia growth factor (VGF) deficient oncolytic vaccinia virus (vvDD) to deliver membrane-bound IL-2 into the tumour microenvironment.